Preliminary experience with paclitaxel for the treatment of relapsed and refractory Hodgkin's disease

Annals of Oncology

Volumn 7, Issue 10, 1996, Pages 1083-1085

  Younes, A ^a   Cabanillas, F ^a   McLaughlin, P W ^a   Hagemeister, F B ^a   Farber, C ^b   Sarris, A ^a   Pate, O ^a   Myers, J ^b   Portlock, C ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Hodgkin's disease; lymphoma; paclitaxel; Taxol

Indexed keywords

PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; HODGKIN DISEASE; HUMAN; MULTICENTER STUDY; PRIORITY JOURNAL;

EID: 0030464822     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010504     Document Type: Article

References (7)

1. Younes A, Sarris A, Melnyk A et al. Three-hour pacliraxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 583-7.
2. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med 1995; 332: 1004-14.
3. Long BH, Fairchild CR. Paclitaxel inhibits progression of mitotic cells to G1 phase by interference with spindle formation without affecting other microtubule function during anaphase and telephase. Cancer Res 1994; 54: 4344-61.
4. Wilson HW, Chabner BA, Bryant G et al. Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas. J Clin Oncol 1995; 13: 381-6.
5. Younes A, Ayoub JP, Hagemeister FB et al. No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour infustion schedule. J Clin Oncol 1996; 14: 543-8.
6. Urba WJ, Longo DL. Hodgkin's disease. N Engl J Med 1992; 326: 678-87.
7. Canellos GP. The second chance for advanced Hodgkin's disease. J Clin Oncol 1992; 10: 175-77.